Erlotinib (Multichem)

Država: Novi Zeland

Jezik: engleski

Izvor: Medsafe (Medicines Safety Authority)

Aktivni sastojci:

Erlotinib hydrochloride 109.267mg equivalent to erlotinib 100mg

Dostupno od:

Multichem NZ Limited

Doziranje:

100 mg

Farmaceutski oblik:

Film coated tablet

Sastav:

Active: Erlotinib hydrochloride 109.267mg equivalent to erlotinib 100mg Excipient: Opadry White 20B58900 Lactose monohydrate Magnesium stearate Microcrystalline cellulose Sodium laurilsulfate Sodium starch glycolate

Tip recepta:

Prescription

Terapijske indikacije:

· Erlotinib is indicated for the first-line and maintenance treatment of patients with advanced (Stage IIIB) or metastatic (Stage IV) non-small cell lung cancer (NSCLC) with activating EGFR mutations. · Erlotinib is also indicated for the treatment of patients with locally advanced or metastatic non small cell lung cancer (NSCLC) who have previously received chemotherapy.

Proizvod sažetak:

Package - Contents - Shelf Life: Blister pack, PVC/Al foil strips in cardboard carton - 30 tablets - 36 months from date of manufacture stored at or below 25°C

Datum autorizacije:

2020-04-15